الرئيسية › دليل الباحثين › Mark Lebwohl

Mark Lebwohl

الانتماء : Icahn School of Medicine at Mount Sinai

• 11منشورات (انتماء أمريكي)
• 1449مجموع المنشورات
• 57348الاستشهادات
• 121مؤشر h

ORCIDOpenAlex

مجالات البحث

• Dermatology and Skin Diseases
• Psoriasis: Treatment and Pathogenesis
• Spondyloarthritis Studies and Treatments
• Nonmelanoma Skin Cancer Studies
• Skin Protection and Aging

المنشورات (11)

• Psoriasis in People With Skin of Color: An Evidence‐Based Update
  2025 · International Journal of Dermatology · استُشهد به 18 مرة
• Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study
  2025 · Video Journal of Biomedicine
• Spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP): a plain language summary of the Effisayil ™ 2 study
  2024 · Future Rare Diseases
• Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
  2023 · The Lancet · استُشهد به 116 مرة
• Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares
  2023 · Dermatology · استُشهد به 26 مرة
• The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity
  2023 · British Journal of Dermatology · استُشهد به 14 مرة
• 33547 Validation of the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) scale for assessing severity of GPP
  2022 · Journal of the American Academy of Dermatology · استُشهد به 2 مرة
• Spesolimab Treatment for People with Flares of Generalized Pustular Psoriasis: A Plain Language Summary of the Effisayil™ 1 Study
  2022 · Future Rare Diseases
• Trial of Spesolimab for Generalized Pustular Psoriasis
  2021 · New England Journal of Medicine · استُشهد به 359 مرة
• Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare
  2021 · BMJ Open · استُشهد به 75 مرة
• 26590 Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis with an acute flare
  2021 · Journal of the American Academy of Dermatology

مجلات النشر

• Future Rare Diseases × 2
• Journal of the American Academy of Dermatology × 2
• International Journal of Dermatology × 1
• Video Journal of Biomedicine × 1
• The Lancet × 1
• Dermatology × 1

المنشورات حسب السنة

• 20252
• 20241
• 20233
• 20222
• 20213

التعاون العلمي

المؤسسات الشريكة : National Taiwan University Hospital · Monash University Malaysia · Inserm · Université Paris Cité · Sultanah Aminah Hospital

بلدان المؤلفين المشاركين : فرنسا · ماليزيا · تايوان · المملكة المتحدة

المؤلفون المشاركون

• Milan J. Anadkat
• Bruce E Strober
• Sushmita Rajeswari
• Kenneth B. Gordon
• Kristina Callis Duffin
• David Hall
• David B. Hall
• Diamant Thaçi
• Junko Takeshita
• Tsen‐Fang Tsai
• Andrew F Alexis
• Mio Nakamura

البيانات البيبليوغرافية مصدرها OpenAlex (قاعدة مفتوحة).